Xeris Biopharma Holdings, Inc. (XERS) Stock
4 of the hedge funds AlphaScala tracks reported XERS in 13F filings for the quarter ended Jun 30, 2026; the largest reported position is D.E. Shaw's at $61.81M. Company insiders reported 0 open-market buys and 10 sales on SEC Form 4 in the 90 days to Oct 21, 2026.
Which hedge funds own XERS?
From 13F filings| Fund | Shares Held | Position Value | Change vs prior Q |
|---|---|---|---|
| D.E. Shaw David Shaw | 7.80M | $61.81M | +0% |
| Citadel Ken Griffin | 665K | $5.26M | -3% |
| Millennium Management Israel Englander | 132K | $1.04M | -94% |
| Renaissance Technologies Jim Simons (founder) | 67K | $533.3K | -85% |
13F holdings as of Jun 30, 2026
Explore all tracked funds →Are Xeris Biopharma Holdings, Inc. insiders buying or selling?
SEC Form 4 filings| Date | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| Oct 1, 26 | Hecht Beth | See Remarks | SELL | 16.7K | $157K |
| Oct 1, 26 | Mcculloch Kevin | See Remarks | SELL | 15.0K | $141K |
| Oct 1, 26 | Pieper Steven | See Remarks | SELL | 5.0K | $47K |
| Sep 28, 26 | Mcculloch Kevin | See Remarks | SELL | 25.0K | $250K |
| Sep 1, 26 | Mcculloch Kevin | See Remarks | SELL | 15.0K | $127K |
| Sep 1, 26 | Hecht Beth | See Remarks | SELL | 16.7K | $141K |
| Sep 1, 26 | Pieper Steven | See Remarks | SELL | 5.0K | $43K |
| Aug 12, 26 | Pieper Steven | See Remarks | SELL | 5.0K | $43K |
| Aug 3, 26 | Hecht Beth | See Remarks | SELL | 16.7K | $134K |
| Aug 3, 26 | Mcculloch Kevin | See Remarks | SELL | 15.0K | $120K |
SEC Form 4 filings as of Oct 21, 2026
See cluster-buy signals across all tickers →XERS price chart
Powered by TradingViewWhat does Xeris Biopharma Holdings, Inc. do?
Xeris Biopharma Holdings, Inc. is a biopharmaceutical company headquartered in Chicago, Illinois. It specializes in developing and commercializing therapies for chronic endocrine and neurological conditions, with a commercial portfolio featuring three key products: Recorlev for treating endogenous Cushing's syndrome in adults unsuitable for surgery, Gvoke for severe hypoglycemia, and Keveyis for Primary Periodic Paralysis. The company leverages proprietary XeriSol and XeriJect formulation platforms to enable innovative subcutaneous and ready-to-use injectable delivery systems, including the recent commercial launch of Gvoke VialDx, a concentrated liquid glucagon for diagnostic use in radiologic procedures via a partnership with American Regent. Xeris Biopharma Holdings, Inc. maintains an active pipeline, highlighted by XP-8121, a novel levothyroxine formulation for potential endocrine applications, supported by recent U.S. patent allowances. These efforts position the company as a focused player in rare disease treatments within the biotechnology sector, emphasizing patient access, intellectual property protection, and commercial expansion in the U.S. market.